Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes

Epigenomics

Volumn 7, Issue 2, 2015, Pages 155-173

  Li, Lili ^a   Zhang, Yuan ^a   Fan, Yichao ^a   Sun, Kun ^b   Su, Xianwei ^a   Du, Zhenfang ^a   Tsao, Sai Wah ^c   Loh, Thomas K S ^d   Sun, Hao ^b   Chan, Anthony T C ^a   Zeng, Yi Xin ^e   Chan, Wai Yee ^b   Chan, Francis K L ^b   Tao, Qian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CpG methylation; MeDIP; Methylome; NPC; Tumor suppressor gene; WNT signaling

Indexed keywords

ADAMTS18 PROTEIN; ADAMTS8 PROTEIN; ADAMTS9 PROTEIN; CACNA2D3 PROTEIN; CADM1 PROTEIN; CCNA1 PROTEIN; CDH4 PROTEIN; DACT2 PROTEIN; DKK2 PROTEIN; DKK3 PROTEIN; DUAL SPECIFICITY PHOSPHATASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR; GONADORELIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; REGULATOR PROTEIN; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SECRETED FRIZZLED RELATED PROTEIN 4; SECRETED FRIZZLED RELATED PROTEIN 5; SLIT2 PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR SOX11; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT PROTEIN; SIGNAL PEPTIDE;

ACTIN FILAMENT; ARTICLE; BASAL CELL CARCINOMA; CANCER GENETICS; CANCER PATIENT; CARCINOMA CELL LINE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; EPITHELIUM CELL; FOCAL ADHESION; GENE DISRUPTION; GENE FUNCTION; GENOME; GENOME-WIDE ASSOCIATION STUDY; HYBRIDIZATION; IMMUNOPRECIPITATION; METHYLOME; NASOPHARYNGEAL EPITHELIAL CELL; NASOPHARYNX CARCINOMA; NOSE MUCOSA; NOSE SMEAR; PHARYNX; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER MICROARRAY HYBRIDIZATION; PROMOTER REGION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; NASOPHARYNX TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; GENES, TUMOR SUPPRESSOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NASOPHARYNGEAL NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84939801715     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/EPI.14.79     Document Type: Article

References (92)

1. Lo KW, To KF, Huang DP Focus on nasopharyngeal carcinoma. Cancer Cell 5(5), 423-428 (2004).
2. Tao Q, Chan AT Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev. Mol. Med. 9(12), 1-24 (2007).
3. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 12(6), 431-441 (2002).
4. Young LS, Rickinson AB Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4(10), 757-768 (2004).
5. Tao Q, Young LS, Woodman C.B., Murray PG. Epstein-Barr virus (EBV) and its associated human cancers - genetics, epigenetics, pathobiology and novel therapeutics. Front. Biosci. 11, 2672-2713 (2006).
6. Kieff E, Rickinson AB Epstein-Barr virus and its replication. In: Fields Virology (5th Edition). Knipe DM, Howley PM (Eds). Walters Kluwer/Lippincott, Williams & Wilkins, PA, USA, 2603-2654 (2007).
7. Lo KW, Chung GT, To KF Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin. Cancer Biol. 22(2), 79-86 (2012).
8. Bei JX, Jia WH, Zeng YX Familial and large-scale case-control studies identify genes associated with nasopharyngeal carcinoma. Semin. Cancer Biol. 22(2), 96-106 (2012).
9. Sung NS, Zeng Y, Raab-Traub N. Alterations on chromosome 3 in endemic and nonendemic nasopharyngeal carcinoma. Int. J. Cancer 86(2), 244-250 (2000).
10. Bei JX, Li Y, Jia WH et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat. Genet. 42(7), 599-603 (2010).
11. Feng BJ, Huang W, Shugart YY et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat. Genet. 31(4), 395-399 (2002).
12. Tse KP, Su WH, Chang KP et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am. J. Hum. Genet. 85(2), 194-203 (2009).
13. Lin DC, Meng X, Hazawa M et al. The genomic landscape of nasopharyngeal carcinoma. Nat. Genet. 46(8), 866-871 (2014).
14. Wolffe AP, Matzke MA Epigenetics: regulation through repression. Science 286 (5439), 481-486 (1999).
15. Jones PA, Baylin SB The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002).
16. Baylin SB, Ohm JE Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6(2), 107-116 (2006).
17. Jones PA, Baylin SB The epigenomics of cancer. Cell 128(4), 683-692 (2007).
18. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
19. Yu DH, Waterland RA, Zhang P et al. Targeted p16Ink4a epimutation causes tumorigenesis and reduces survival in mice. J. Clin. Invest. 124(9), 3708-3712 (2014).
20. Li LL, Shu XS, Wang Z.H., Cao Y., Tao Q. Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. Chin. J. Cancer 30(4), 231-239 (2011).
21. Lo KW, Cheung ST, Leung SF et al. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res. 56(12), 2721-2725 (1996).
22. Lo KW, Kwong J, Hui AB et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res. 61(10), 3877-3881 (2001).
23. 2+-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc. Natl Acad. Sci. USA 104(30), 12353-12358 (2007).
24. Cheung HW, Ching YP, Nicholls JM et al. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. Mol. Carcinog. 43(4), 237-245 (2005).
25. Hui AB, Lo KW, Kwong J et al. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma. Mol. Carcinog. 38(4), 170-178 (2003).
26. Lung HL, Cheng Y, Kumaran MK et al. Fine mapping of the 11q22-23 tumor suppressive region and involvement of TSLC1 in nasopharyngeal carcinoma. Int. J. Cancer 112(4), 628-635 (2004).
27. Ying J, Li H, Seng TJ et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 25 (7), 1070-1080 (2006).
28. Cheng Y, Geng H, Cheng SH et al. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res. 70(16), 6516-6526 (2010).
29. Hutajulu SH, Indrasari SR, Indrawati LP et al. Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. Mol. Cancer 10, 48 (2011).
30. Yang X, Dai W, Kwong DL et al. Epigenetic markers for non-invasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. Int. J. Cancer doi:10.1002/ijc.29192 (2014) (Epub ahead of print).
31. Tsao SW, Wang X, Liu Y et al. Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim. Biophys. Acta 1590(1-3), 150-158 (2002).
32. Li HM, Man C, Jin Y et al. Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase. Int. J. Cancer 119(7), 1567-1576 (2006).
33. Cheung ST, Huang DP, Hui AB et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int. J. Cancer 83(1), 121-126 (1999).
34. Qiu GH, Tan LK, Loh KS et al. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 23(27), 4793-4806 (2004).
35. Li L, Su X, Choi G.C., Cao Y., Ambinder RF, Tao Q. Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK-and B-cell origins. BMC Cancer 12, 125 (2012).
36. Shu XS, Li L, Ji M et al. FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. Carcinogenesis 34 (9), 1984-1993 (2013).
37. Busson P, Ganem G, Flores P et al. Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int. J. Cancer 42(4), 599-606 (1988).
38. Huang da W., Sherman BT, Lempicki RA Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4(1), 44-57 (2009).
39. Dennis G Jr, Sherman B.T., Hosack DA et al. DAVID: Database for Annotation, Visualization, and Integrated Disc over y. Genome Biol. 4(5), P3 (2003).
40. Kyoto Encyclopedia of Genes and Genomes (KEGG) database. www.genome.jp/kegg/kegg1.html
41. Li L, Ying J, Li H et al. The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/beta-catenin signaling and silenced in common carcinomas. Oncogene 31(34), 3901-3912 (2012).
42. Li L, Ying J, Tong X et al. Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting beta-catenin and AKT signaling but frequently methylated in common carcinomas. Cell Mol. Life Sci. 71(11), 2179-2192 (2014).
43. Choi GC, Li J, Wang Y et al. The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. Mol. Cancer Res. 12(2), 228-238 (2014).
44. Du W, Wang S, Zhou Q et al. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. Oncogene 32(28), 3319-3328 (2013).
45. Wang Y, Li J, Cui Y et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res. 69(12), 5194-5201 (2009).
46. Lee KY, Geng H, Ng KM et al. Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene 27(39), 5267-5276 (2008).
47. He D, Zeng Q, Ren G et al. Protocadherin 8 is a functional tumor suppressor frequently inactivated by promoter methylation in nasopharyngeal carcinoma. Eur. J. Cancer Prev. 21(6), 569-575 (2012).
48. Yin X, Xiang T, Li L et al. DACT1, an antagonist to Wnt/ beta-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer. Breast Cancer Res. 15(2), R23 (2013).
49. Cheng Y.Y., Yu J, Wong YP et al. Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br. J. Cancer 97(7), 895-901 (2007).
50. Xiang T, Li L, Yin X et al. Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal Wnt/beta-catenin signalling and apoptosis regulation in breast cancer cells. J. Cell Mol. Med. 17(10), 1236-1246 (2013).
51. Tao Q, Huang H, Geiman TM et al. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum. Mol. Genet. 11(18), 2091-2102 (2002).
52. Tao Q, Swinnen LJ, Yang J, Srivastava G., Robertson KD, Ambinder RF. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am. J. Pathol. 155 (2), 619-625 (1999).
53. Tao Q. Cancer research in an era when epigenetics is no longer 'epi' - challenges and opportunities. Chin. J. Cancer 32(1), 1-2 (2013).
54. Li H, Li J, Su Y et al. A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth. Oncogene 33(24), 3109-3118 (2014).
55. Lung HL, Lo PH, Xie D et al. Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma. Int. J. Cancer 123(2), 401-408 (2008).
56. Jin H, Wang X, Ying J et al. Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene 26(53), 7490-7498 (2007).
57. Wong AM, Kong KL, Chen L et al. Characterization of CACNA2D3 as a putative tumor suppressor gene in the development and progression of nasopharyngeal carcinoma. Int. J. Cancer 133(10), 2284-2295 (2013).
58. Yanatatsaneejit P, Chalermchai T, Kerekhanjanarong V et al. Promoter hypermethylation of CCNA1, R ARRES1, and HRASLS3 in nasopharyngeal carcinoma. Oral Oncol. 44(4), 400-406 (2008).
59. Du C, Huang T, Sun D et al. CDH4 as a novel putative tumor suppressor gene epigenetically silenced by promoter hypermethylation in nasopharyngeal carcinoma. Cancer Lett. 309(1), 54-61 (2011).
60. Seng TJ, Low JS, Li H et al. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene 26(6), 934-944 (2007).
61. Low JS, Tao Q, Ng KM et al. A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Oncogene 30(16), 1923-1935 (2011).
62. Wong VC, Chen H, Ko JM et al. Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int. J. Cancer 130(1), 83-95 (2012).
63. Loyo M, Brait M, Kim MS et al. A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int. J. Cancer 128(6), 1393-1403 (2011).
64. Kwong J, Lo KW, To K.F., Teo PM, Johnson PJ, Huang DP. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 8(1), 131-137 (2002).
65. Challouf S, Ziadi S, Zaghdoudi R., Ksiaa F, Ben Gacem R, Trimeche M. Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. Clin. Chim. Acta. 413(7-8), 795-802 (2012).
66. Li J, Gong P, Lyu X., Yao K, Li X, Peng H. Aberrant CpG island methylation of PTEN is an early event in nasopharyngeal carcinoma and a potential diagnostic biomarker. Oncol. Rep. 31(5), 2206-2212 (2014).
67. Cheung AK, Lung HL, Hung SC et al. Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res. 68(19), 8137-8145 (2008).
68. Wong TS, Tang KC, Kwong DL et al. Differential gene methylation in undifferentiated nasopharyngeal carcinoma. Int. J. Oncol. 22(4), 869-874 (2003).
69. Zhou L, Jiang W, Ren C et al. Frequent hypermethylation of RASSF1A and TSLC1, and high viral load of Epstein-Barr Virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues. Neoplasia 7(9), 809-815 (2005).
70. Mo Y, Midorikawa K, Zhang Z et al. Promoter hypermethylation of Ras-related GTPase gene RRAD inactivates a tumor suppressor function in nasopharyngeal carcinoma. Cancer Lett. 323(2), 147-154 (2012).
71. Wong TS, Kwong DL, Sham JS et al. Promoter hypermethylation of high-in-normal 1 gene in primary nasopharyngeal carcinoma. Clin. Cancer Res. 9(8), 3042-3046 (2003).
72. Zhang S, Li S, Gao JL Promoter methylation status of the tumor suppressor gene SOX11 is associated with cell growth and invasion in nasopharyngeal carcinoma. Cancer Cell Int. 13(1), 109 (2013).
73. Li L, Tao Q, Jin H et al. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin. Cancer Res. 16(11), 2949-2958 (2010).
74. CpG island searcher. http://ccnt.hsc.usc.edu/cpgislands2
75. Jiang X, Tan J, Li J et al. DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 13(6), 529-541 (2008).
76. Kang GH, Lee S, Kim WH et al. Epstein-Barr viruspositive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am. J. Pathol. 160(3), 787-794 (2002).
77. Matsusaka K, Kaneda A, Nagae G et al. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 71(23), 7187-7197 (2011).
78. Chang MS, Uozaki H, Chong JM et al. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin. Cancer Res. 12(10), 2995-3002 (2006).
79. Feinberg A.P. Epigenomics reveals a functional genome anatomy and a new approach to common disease. Nat. Biotechnol. 28 (10), 1049-1052 (2010).
80. Gupta R, Nagarajan A, Wajapeyee N. Advances in genome-wide DNA methylation analysis. Biotechniques 49(4), iii-xi (2010).
81. Wang J, Xia Y, Li L et al. Double restriction-enzyme digestion improves the coverage and accuracy of genome-wide CpG methylation profiling by reduced representation bisulfite sequencing. BMC Genomics 14, 11 (2013).
82. Dedeurwaerder S, Defrance M, Bizet M., Calonne E, Bontempi G, Fuks F. A comprehensive overview of Infinium HumanMethylation450 data processing. Brief. Bioinform. 15(6), 929-951 (2014).
83. Chen YA, Lemire M, Choufani S et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics 8(2), 203-209 (2013).
84. Harper KN, Peters BA, Gamble MV Batch effects and pathway analysis: two potential perils in cancer studies involving DNA methylation array analysis. Cancer Epidemiol. Biomarkers Prev. 22 (6), 1052-1060 (2013).
85. Down TA, Rakyan VK, Turner DJ et al. A Bayesian de convol ut ion strategy for immunoprecipitation-based DNA methylome analysis. Nat. Biotechnol. 26(7), 779-785 (2008).
86. Weber M, Davies J J, Wittig D et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 37(8), 853-862 (2005).
87. Matsumura S, Imoto I, Kozaki K et al. Integrative array-based approach identifies MZB1 as a frequently methylated putative tumor suppressor in hepatocellular carcinoma. Clin. Cancer Res. 18(13), 3541-3551 (2012).
88. Heller G, Babinsky VN, Ziegler B et al. Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. Carcinogenesis 34(3), 513-521 (2013).
89. Morris MR, Ricketts CJ, Gentle D et al. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene 30(12), 1390-1401 (2011).
90. Brebi P, Maldonado L, Noordhuis MG et al. Genome-wide methylation profiling reveals zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population. Epigenetics 9(2), 308-317 (2014).
91. Cheung HH, Lee TL, Davis A.J., Taft DH, Rennert OM, Chan WY. Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br. J. Cancer 102(2), 419-427 (2010).
92. Chan SL, Cui Y, Van Hasselt A et al. The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab. Invest. 87(7), 644-650 (2007).